Cross-Sector entity
All 2 tracked stories fall under one category: clinical-trial. Of the tracked stories, 2 of 2 also mention Nature, the most common co-covered peer. The 7-day window averages about 2 stories each week. We currently track 2 Cross-Sector stories that mention Shanghai Jiaotong University School of Medicine, published between July 26, 2026 and August 1, 2026.
2 verified stories tracked
Last mentioned: Aug 1, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: clinical-trial. Of the tracked stories, 2 of 2 also mention Nature, the most common co-covered peer. The 7-day window averages about 2 stories each week. We currently track 2 Cross-Sector stories that mention Shanghai Jiaotong University School of Medicine, published between July 26, 2026 and August 1, 2026. Each carries 2 original sources on average.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Shanghai Jiaotong University School of Medicine. Shared-story counts are live from our verified record — not editorial picks.
Shanghai Jiaotong University launches investigation
The university forms a working group to comprehensively investigate the clinical trial and the associated Nature paper.
Joint investigation report published
Science magazine and Retraction Watch release findings detailing the undisclosed death and ethical lapses, bringing the case to public attention.
University investigation launched
Shanghai Jiao Tong University School of Medicine announces a special working group to investigate and promises 'serious action'.
Investigative report published
Science and Retraction Watch publish a joint exposé revealing the death and lack of disclosure, triggering international scrutiny.
Mei receives gene-editing therapy
Six-year-old girl with rare cognitive delay condition receives spinal infusion of trillions of engineered viruses in an experimental trial.
Fatal gene-editing trial conducted
A young girl receives an experimental gene-editing treatment for a developmental-delay-linked genetic defect at Xinhua Hospital; she later dies, an outcome the ethics board deems treatment-related.
He Jiankui gene-edited babies scandal breaks
Chinese scientist He Jiankui announces the birth of the world’s first gene-edited babies, triggering global outrage and prompting China to tighten research regulations.
A young girl's death in an undisclosed gene-editing trial, funded by $860,000 from her parents, has triggered an investigation at Shanghai Jiaotong University. The case exposes critical ethics gaps in China's surging biopharma sector and raises alarms for investors, partners, and regulators worldwide.
Source: yahoo.com · egyptindependent.com
The death of a young patient in a Chinese gene-editing trial, hidden from a subsequent Nature publication, sends shockwaves through the biotech sector. Industry leaders must grapple with the implications for gene therapy research integrity, funding, and the race to deliver transformative neurological treatments.
Source: channelnewsasia.com · straitstimes.com
